"THE LAB-PHARMACY NEXUS: UNVEILING THE CONVERGENCE OF SCIENTIFIC RESEARCH AND MEDICATION MANAGEMENT"
A REVIEW ARTICLE IN IMPORTANCE OF LAB-PHARMACY INTERPLAY.

Fahad Saad Fahad Alothaymin[1]*, Faisal Fahad Ghazzai Almutairi[2], Abdulelah Mohsen Alharbi[3], Mohammed Ali Alahmar[4], Wazirah Mohammed Fawaze Alanazi[5], Mishal Fahad Aldossary[6], Haya Thafer Mohamed Althafer[7], Nouf Wasel Aljohani[8], Mustafa Othman Albulushi[9], Abeer Mohammad Abduljabbar[10]

Abstract:
The synergies and vital interdependence between scientific research labs and pharmacies within the healthcare ecosystem have been thoroughly explored in this topic. Scientific research labs were portrayed as centers of creativity, experimentation, and cross-disciplinary cooperation that shaped how we perceive the natural world. Pharmacies were acknowledged as essential to patient care for their ability to dispense prescription drugs, promote health, and guarantee regulatory compliance. The discussion shed light on situations in which miscommunication between pharmacies and labs resulted in avoidable mistakes in medicine administration. The story went on to highlight the growing importance of pharmacists in the monitoring of therapeutic drugs, chronic illness care, and diagnostics. The need for collaboration between lab technicians and pharmacists was emphasized as a means of promoting innovation, managing the challenges associated with medication monitoring, and guaranteeing the best possible outcomes for patients. This comprehensive investigation highlights how important it is to collaborate seamlessly in order to promote patient safety, advance healthcare innovation, and improve the standard of care as a whole.

Key Words: Laboratories, Pharmacies, Interplay, Lab-Pharmacy Nexus, Linkage.

[1*,2,3,4,5,6,7,8,9,10]KSA, Ministry of Health

***Corresponding Author: -** Fahad Saad Fahad Alothaymin
*KSA, Ministry of Health

DOI: 10.53555/ecb/2022.11.6.66

Introduction and Background:

Scientific research labs are specialized centers dedicated to knowledge discovery, invention, analysis of different biological samples, and exploration in a variety of scientific fields. These institutions act as the hub for scientific investigation, where scientists conduct studies, evaluate information, and develop novel hypotheses to deepen our understanding of the natural world. The research process in these labs is shaped by a few fundamental ideas. The basic experimentation procedure is at the heart of scientific research labs. To test theories and obtain empirical data that helps them make inferences and improve their comprehension of particular phenomena, researchers plan controlled experiments. The scientific method relies heavily on this practical approach [1].

Scientific research labs are vibrant hubs of creativity and learning. In these labs, scientists explore new ground in search of original answers to challenging issues. Their goal is to push the limits of human knowledge and make a positive impact on the disciplines of science, technology, and medicine. One thing that sets apart scientific research labs is collaboration. Scholars from different backgrounds collaborate on projects together, each contributing special knowledge and insights. As insights from many domains converge, this interdisciplinary collaboration boosts the possibility for revolutionary discoveries and stimulates creativity.

Thorough data analysis is an essential component of scientific inquiry. Through the use of statistical techniques and computing instruments, researchers analyze data and draw significant conclusions. The validity and trustworthiness of study findings are directly impacted by the correctness of data analysis, underscoring the significance of careful examination. Peer review is seen by scientists as essential to guaranteeing the caliber and validity of research. When scientists publish their work in journals, their colleagues review it and comment on the technique, findings, and conclusions. Publication in respectable journals is an important step toward increasing the understanding of the scientific community as a whole, promoting transparency, and spreading new knowledge [2].

Pharmacies and scientific research facilities have always operated in separate sectors of the healthcare sector. The goal of laboratories was to generate new discoveries by means of experimental research, findings publication, analysis of different types of samples, and ultimately product commercialization. pharmacies with a focus on compounding and distributing drugs in compliance with industry guidelines and prescription orders.

The distinctions between these two industries are starting to become less clear, though, due to recent developments in fields like customized medicine, biologics development, and specialty treatments. In an effort to accelerate the application of discoveries to patient care, laboratories are currently conducting more applied research and product formulation. Similarly, pharmacies now carry out quality control and complex analytics that were formerly restricted to research settings. This new alliance reflects a deeper convergence of operations and workflows between pharmacies and labs.

The article's thesis is that, as a result of recent advancements in technology and scientific research, the domains of pharmacy and scientific research laboratories are progressively merging. Coordinated research and production skills are necessary for personalized medicine techniques that customize medicines based on individual genetics and biomarkers. Comprehensive analytics are necessary for large molecule biologics and biosimilars during development and distribution. To optimize patient results, integrated research, production, and distribution approaches are also required for cell and gene therapies.

The pace of therapeutic innovation necessitates more collaboration between researchers and practitioners in order to give novel treatments. The research, development, and patient care facets that are now bridging the gap between pharmacies and labs will be discussed in this article. In order to better serve increasingly specialized patient populations, it will examine instances of their merging responsibilities and functions. There are potential for higher standards as well as new opportunities and challenges throughout this lab-pharmacy nexus as a result of the merger of these traditionally independent domains.

Lab-Pharmacy Nexus: How the Interplay Solves the Issue of Medical Errors:

A physician might continue an antibiotic even though blood cultures show resistance, fail to perform recommended liver or muscle enzyme tests in patients taking troglitazone or cerivastatin sodium, prescribe potassium supplements for a patient who is hyperkalemic, and fail to modify the dosage of gentamicin in a patient with impaired renal function. Even though they happened often, these errors may have been avoided if information systems from the laboratories and pharmacies had communicated more effectively [3-5].

Medication mistakes linked to laboratory problems are a frequent risk to patient safety both within and

outside of hospitals. According to a study, out of 100 admissions, 6.5 had adverse medication events, of which 28% were considered preventable. Common mistakes were associated with drug dosage and laboratory parameter selection. Another study that used computerized screening found that 5% of 13,727 patients had possible drug problems; 44.9% of positive screens had drug-related laboratory abnormalities. Excessive dosage for patients with compromised renal and hepatic function was the leading error type (13.9% of all errors) in over 2,100 pharmaceutical errors detected by pharmacists. Adverse medication events are also frequent in assisted living facilities, where one of the main causes of errors is insufficient laboratory monitoring, especially with regard to anticoagulant therapy [6].

Medication-related issues continue to arise outside of hospitals despite the paucity of outpatient data; monitoring deficiencies are particularly common. According to one study, 79% of adverse drug events that were discovered by associating medications with "signals" in the lab were frequently overlooked. The clinical laboratory and pharmacy show a notable separation, despite the fact that laboratory data is essential for managing and choosing medications. The laboratory and pharmacy work in tandem to monitor the effects of drugs, with the pharmacy handling medication dispensing. But seldom, especially in outpatient settings, do these departments' staff, work procedures, and information systems communicate with one another. This gap also exists in quality improvement programs, which frequently fail to take advantage of using laboratory and pharmacy data to reduce errors and improve patient care. The crucial relationship between laboratory and medication errors is not sufficiently covered in recent symposia on enhancing clinical use of laboratory data and extensive publications on reducing medication errors [7-9].

Lab-Pharmacy Nexus: How Interplay Solves the Healthcare Providers Shortage:

There is an increasing need for clinical services at pharmacies due to the growing scarcity of healthcare practitioners and the rise of healthcare deserts. More and more pharmacies are assuming clinical responsibilities that call for laboratory assistance. Healthcare expenses have grown exponentially, outpacing previously stable inflation rates, even as healthcare deserts continue to exist. In contrast to the healthcare sector, where expenses have increased by over 200%, consumer goods prices have dropped by 40% to 80% over the past 20 years, including TVs, mobile phones, toys, and computer software [10].

The problems associated with missed clinical visits and first-fill drop-offs have gotten worse recently, in addition to the skyrocketing costs of healthcare. Missed clinical visits were a bigger problem as a result of the COVID-19 pandemic, with a net reduction of 10% below pre-pandemic levels. While prescription fills are still around 20% below pre-COVID-19 pharmacy fill levels, diagnostics have recovered to a 5% decrease below pre-pandemic levels. Patients often approach more advanced stages of disease due to a combination of chronic disorders that are either poorly managed or go undiagnosed, and the difficulties in getting healthcare. Diabetes patients show end-organ damage, and cancer patients are diagnosed with metastatic cancer [11].

This emphasizes how important it is for pharmacists and labs to work together to improve patient care in the changing healthcare environment. By working together, pharmacists and labs can achieve three major advantages that enhance patient outcomes and care while also boosting income streams. Pharmacies have made it easier to obtain basic care and treatment in the current situation, where just 11% of doctors work in rural areas despite 20% of Americans living there. 90% of Americans currently reside within two miles and 95% within five miles of a drugstore. Patient preferences are in line with the availability of care from pharmacists. Eighty percent of seniors want access to local pharmacies for immunizations, testing, and treatments for infectious diseases, according to a recent opinion poll. Additionally, 85% of respondents think that Congress must guarantee more widespread access to pharmacy services. 51% of Americans visit pharmacies for services including routine screenings, COVID-19 testing, and vaccinations; this number much exceeds visits to doctors and other healthcare professionals by a factor of ten. This indicates that pharmacies are emerging as centers for health and wellness services [11].

Pharmacists are driving innovation in the present landscape of pharmacy and diagnostics convergence, introducing concepts like "screen and treat" and "test and treat." All around the nation, pharmacists are testing patients for a range of ailments, such as HIV, pharmacogenomics, colon cancer, and cholesterol. Standard laboratory testing and genetic testing is in great demand for individualized therapies for major illnesses as well as newer conditions including obesity and thalassemia. Next-generation sequencing and pharmacogenomics are being used to improve

clinical effectiveness based on patients' genomic profiles. Prior permission policies from payors have made laboratories necessary, as these services cannot be rendered without routine quick testing and low-acuity type tests. The mutually beneficial partnership between pharmacies and labs has enormous potential to influence how healthcare is delivered in the future [11].

Lab-Pharmacy Nexus: Areas of Interplay:

1. Medication Selection:

Cutting-edge software has been created to examine if a patient's prescription drug is listed on their insurance company's formulary, primarily based on cost concerns. Nevertheless, despite established clinical benefits, institutions' ability to determine safety contraindications based on test results is severely lacking. A recent survey, for instance, found that large Chicago, Illinois hospitals and clinics did not have systems in place to automatically stop prescribing potassium when a patient had elevated serum potassium levels, metformin hydrochloride in the event of azotemia, or an angiotensin-converting enzyme inhibitor after a positive pregnancy test. On the other hand, specialized medication therapies are indicated by specific clinical laboratory abnormalities. Certain situations require pharmaceutical interventions, such as a regularly raised glucose or hemoglobin A1c level without a prescription for hypoglycemic medicines, or a noticeably elevated thyrotropin (TSH) level without a later prescription for levothyroxine sodium (or a repeat test). If these steps are not taken, notifications ought to be sent to ensure rapid replies [12-13].

To add to the data, new research suggests that prescription decision support systems might greatly improve patient safety by incorporating safety contraindications based on test results. Institutions that have implemented these measures have documented a significant decrease in adverse drug events associated with drugs that are not appropriate. Furthermore, these treatments have a financial impact that goes beyond only saving money on averting unfavorable outcomes because they also optimize hospital resources and enhance patient care generally. There is still a significant acceptance gap in laboratory-based safety contraindications among healthcare institutions, despite the obvious therapeutic benefits and possible cost savings linked with their implementation. According to research, closing this gap can be achieved by providing thorough training programs for medical personnel and utilizing technology developments in decision support systems to ensure that patient safety is given first priority in prescription procedures [14].

2. Medication Dose:

A review of individuals with digoxin toxicity found that 32% had renal insufficiency, frequently with no appropriate dosage modification. 70% of medication orders for patients with impaired creatinine clearance were incorrectly prescribed with excessively high doses or frequencies, according to recent research. This was especially true for prescriptions including medications excreted renally or considered nephrotoxic. Even with several published guidelines that have been augmenting prescription labels with clear instructions for decades, clinicians still need more dependable techniques to guarantee proper renal dosing. Systematic efforts to automate the computation of creatinine clearance and modified dosages are urgently needed, as it is impossible to expect clinicians to memorize changes in dosages for multiple medicines and to determine which patients require such adjustments and to what extent. Reduced albumin levels, high bilirubin levels, or higher aminotransferase levels suggest that hepatically cleared drug dosages should be reduced, even though there is no comparable technique to calculate hepatic clearance [15].

Many medications, such as anticoagulants, endocrine or hormonal medications, and anticonvulsants, necessitate continuing titration based on blood drug levels or other clinical laboratory indications of their biological effects after the initial dose selection. Nonetheless, there are significant differences in the frequency, appropriateness, and achievement of desired levels of testing. To overcome these obstacles, the best frequency for these tests must be established, and guidelines for dose modifications depending on test findings must be established. This procedure can be made more efficient by using electronic data connected to drug laboratories to create graphic flow charts for drug dosage and test results. Clinical professionals can respond to changes in test results more scientifically by using statistical process control, a tried-and-true method in other industries. With the help of this technology, doctors and patients alike can graph test results over time, such as glucose or anticoagulation tests, in connection to medication dosages. These charts help determine whether to adjust medicine dosages by showing whether variations in levels are actually out of control (requiring a change) or random (saying no change is necessary). When compared to doctors' traditional hit-and-miss approach, diabetic patients using statistical process

control methods have been more successful in reaching target control levels. One practice reported a significant decrease in average fasting blood glucose from 187 to 110 mg/dL (10.4 to 6.1 mmol/L) and a drop in hemoglobin A1c concentration from 10.5% to 7.2% [16-17].

3. Financial Issues:

In contemporary healthcare, pharmacists are assuming an increasingly pivotal role as providers, particularly in the realm of diagnostics and treatment. This paradigm shift is underscored by the scheduling of office hours by pharmacists nationwide, signifying their emergence as a new cadre of healthcare providers. Notably, pharmacists now possess the authority to order and prescribe medications in select states, with almost 40 states recognizing their direct access to testing and acknowledging them as providers. This recognition is fortified by the Public Readiness and Emergency Preparedness Act (PREP Act), initially established in 2005 and reaffirmed in 2020, which empowers pharmacists to prescribe oral medication, a crucial development in the context of managing patients with COVID-19 [18].

The collaboration between retail, specialty, and outpatient pharmacies and laboratories is not only beneficial for enhancing patient care but also holds substantial financial advantages. The financial landscape is notably influenced by the surge in sales of specialty oncology and immunotherapy medications, which now constitute 55% of all pharmacy sales, marking a significant increase from 28% in 2011. The growth rates for autoimmune medications and oncology drugs during this period were 459% and 346%, respectively, highlighting the considerable financial stakes involved. However, the unique cost considerations associated with autoimmune therapies, often reaching hundreds of thousands of dollars, underscore the need for specialized financial strategies [19].

Specialty pharmacies, dealing with high-value medications, face the imperative of efficiently gathering pre- and post-dispensing lab test results. Specific drugs in this category necessitate rigorous monitoring, such as Hepatitis C medications requiring viral load checks, HIV pre- and post-exposure prophylaxis requiring testing, and Clozapine requiring verification of white blood cell count before dispensing. For the optimal synergy between laboratories, specialized diagnostics, and pharmacies, a profound understanding of several key dynamics is essential. This includes acknowledging the real-world impact of diagnostics on treatment decisions, crucial for advancing personalized medicine initiatives. Moreover, recognizing the potential for enhanced patient convenience and affordability as certain services transition from the physician's office to the pharmacy is vital. The evolving regulatory landscape further empowers pharmacists to provide expanded clinical services, thereby ensuring improved treatment utilization, coverage, and an enhanced overall experience for both patients and providers [20].

The escalating demand from payors for comprehensive data on service tests aligns with the burgeoning digital ecosystem, directing an increasing number of patients toward pharmacy facilities. This paradigm shift creates a heightened demand for lab services within the pharmacy setting, substantiating the necessity for a robust collaboration between laboratories and pharmacies to meet the evolving needs of healthcare delivery.

4. Case Monitoring:

Improving the intelligence of lab test findings requires a thorough knowledge of the drugs that a patient is currently taking. When a patient is also taking hepatotoxic medications, for example, the significance of seemingly insignificant liver abnormalities increases. Similarly, hypokalemia has particular consequences for people who are also on digoxin. Prescription commencement facts, such as the date and time of prescription, must be integrated with the ability to intelligently evaluate changes in laboratory parameters over time in order to establish links between drug information and laboratory results. The significance of patients' past laboratory results in spotting subtle alterations that would go unnoticed otherwise is highlighted by this method [21].

To guarantee patient safety, several drugs require routine or baseline laboratory monitoring. The withdrawal of troglitazone from the US market was notably caused by rare but potentially fatal cases of hepatotoxicity. Less than 5% of patients at an academic hospital received the monthly testing required by the Food and Drug Administration for troglitazone's safe use, despite claims made by the drug's manufacturer and the US Food and Drug Administration regarding its safety when properly monitored. There has been a comparable monitoring breach for statin cholesterol-lowering medications. A secure system must be established before integrated computerized scheduling and tracking can be used, because of the practical difficulties involved in organizing drug-related laboratory monitoring. The incorporation of technology becomes necessary to provide the consistent and methodical observation that is

necessary for patient safety and compliance with legal requirements [22].

5. Data Learning, Development, and Interpretation:

Previous studies by Friedman et al. and Young , as well as more recent studies by Finnish researchers Gronroos et al. and Forsstrom et al., highlight how important it is for the laboratory to know what medications a patient is taking in order to avoid results being misinterpreted, particularly when medications affect laboratory measurements. Notably, a survey concentrating on specimens sent for hormone tests found that nearly 40% of patients tested for thyroid-stimulating hormone (TSH) had such conflicts, and 11% of patients were currently using one or more possibly conflicting medicines. The severity of this problem led Finnish laboratory experts to create a database that lists patients' medication profiles, proving that this improved the accuracy of interpreting test results from the laboratory. Conflicts between medications and test results are often overlooked in other parts of the world, mostly because there is not enough information available about in vitro laboratory interference or in vivo biologic effects. Although several conflicts have been identified, the extent and clinical importance of these conflicts are often not well-supported by the available data [23-24].

In laboratory analysis, basic follow-up concerns, including how urgent it is to treat a 300 mg/dL glucose level, may be more successfully addressed if the laboratory knew whether the patient was on glucose-lowering medication, a sign of recognized diabetes. When a patient takes erythropoietin for anemia, the treatment plan should be different than when a patient takes a nonsteroidal anti-inflammatory medicine for a lowering hematocrit. In order to effectively interpret drug levels and ensure that specimen collection is done appropriately, the laboratory must have a thorough understanding of both the medications a patient is taking and the timing of their administration [25].

Data mining using strong search algorithms and large connected datasets is a paradigm-shifting strategy for scientific research with significant promise to improve healthcare treatment in the field of learning and improvement. Similar breakthroughs to the Human Genome Project demonstrate the enormous potential of systematic data gathering in conjunction with phenotypic data to enable the discovery of novel insights. Integration of laboratory and pharmacy data can lead to similar advancements in understanding of drug effects and outcomes. Although correlations between pharmacological substances and anomalies in clinical laboratory tests are regarded as theories requiring further investigation, they are important indicators for the prompt identification of side effects [26].

Practically speaking, the integration of pharmacy and laboratory data can help determine whether patients should be monitored appropriately while taking particular medications and how quickly abnormal laboratory results should be addressed. This quality assurance function has been crucial in identifying improper laboratory testing procedures and recording instances where advised monitoring has not been obtained. Instances when patients were given antibiotics to which their diseases were resistant or treated without getting the necessary cultures, for example, have been exposed by discrepancies between microbiology data and medication prescriptions. By identifying diabetes patients taking hypoglycemic drugs through pharmacy records and connecting these records to serial renal function data, population-based tracking of diabetic outcomes can also be made easier. To determine past quality trends, queries about certain medications, lab tests, doctors, or time periods can be made using appropriately connected laboratory-pharmacy databases.

6. Managing High Risk Drugs and Chronic Diseases:

A closer working relationship between laboratory technicians and pharmacists has been fueled by the growing range of laboratory tests available and the rising demand for therapeutic drug monitoring (TDM). According to Dr. Bill Clarke of the Johns Hopkins University School of Medicine, this kind of alliance becomes more important when it comes to newer medications that require a more advanced monitoring strategy [27].

Drugs like busulfan in cancer treatment or mycophenolate in organ transplantation, for example, require thorough supervision from a multidisciplinary team that goes beyond individual physicians. With the complexity of medical knowledge increasing, decision support tools—which the laboratory and pharmacy can help with—become essential for providing the best possible care for patients. At Johns Hopkins, for instance, specialized oncology pharmacists are essential in overseeing medications such as busulfan, closely collaborating with the laboratory to assess pharmacokinetics and guarantee accurate dosage modifications [27].

Another exemplary case that is closely observed through laboratory measures at Johns Hopkins is the anti-fungal drug voriconazole. When

medication levels differ from what is expected, regular conversations take place between the laboratory and pharmacists who specialize in infectious illnesses or oncology. This tendency of collaboration results from a paradigm change in the ownership of clinical care, which gives lab technicians and pharmacists more responsibilities. Both professions are encouraged to play a more collaborative consulting role in the emerging healthcare model. Because of their common experience, pharmacists and lab technicians are able to collaborate and consult more frequently due to their divided responsibilities, which improves patient care.

This spirit of cooperation carries over to more expansive projects, like the multidisciplinary Pharmacy, Nutrition, and Therapeutics (PNT) group at Froedtert Hospital. In this case, collaboration entails overseeing the formulary of the organization as well as making sure that drugs are used appropriately and are safe and effective. The collaboration between the pharmacy and the laboratory helps to put changes into practice, including changing the reference intervals for therapeutic drug monitoring tests or the testing procedures. The paper emphasizes the value of a mutually beneficial partnership in which laboratories gain from the pharmacists' knowledge of preanalytical factors and suitable sample collection, and pharmacists' profit from rapid TDM results for dosage modifications. Beyond TDM, integrated delivery systems such as Group Health Cooperative (GHC) in Seattle are attempting to monitor patients with chronic conditions by methodically cross-referencing lab and pharmaceutical data. This creative collaboration has the potential to enhance patient outcomes and guarantee the safe and efficient administration of pharmaceuticals [27].

Conclusion:

Finally, the conversation has offered a thorough examination of the mutually beneficial connections that exist between pharmacies, scientific research facilities, and the changing face of healthcare delivery. Key principles like experimentation, invention, data analysis, and peer review are embodied in scientific research labs, which have evolved as epicenters of knowledge, creativity, and interdisciplinary collaboration. These labs are essential to expanding our knowledge of the natural world and fostering innovations across a range of disciplines. In contrast, pharmacies were described as essential parts of the healthcare system that dispensed drugs, provided patient counseling, promoted health, and complied with legal requirements. Pharmaceutical safety, health promotion, regulatory compliance, and patient counseling are some of the fundamental ideas related to pharmacies. Pharmacies and scientific research labs were acknowledged as essential components of healthcare, with each making a distinct contribution to the health of people and communities.

The ensuing investigation examined the vital necessity of improved communication and cooperation between pharmacies and laboratories, particularly with regard to patient care, medication safety, and error prevention. The instances of communication breakdowns between these entities that resulted in avoidable mistakes in medicine administration and patient outcomes were highlighted by the examples given. Moreover, the conversation broadened to highlight the relationship between diagnosis and treatment, with pharmacists becoming more involved in clinical services, monitoring therapeutic drugs, and managing chronic illnesses. In order to successfully navigate the intricacies of medication monitoring, guarantee the best possible outcomes for patients, and promote a data-driven approach to healthcare delivery, collaboration between laboratorians and pharmacists has emerged as essential. In order to spur innovation, improve patient safety, and raise the standard of healthcare delivery in a constantly changing environment, laboratories and pharmacies must work together seamlessly. This comprehensive investigation emphasizes the connections between pharmaceutical practices, scientific research, and patient care.

References:

1. Schiff, G. D., Klass, D., Peterson, J., Shah, G., & Bates, D. W. (2003). Linking laboratory and pharmacy: opportunities for reducing errors and improving care. *Archives of internal medicine*, *163*(8), 893-900.
2. Woodcock, J., & Woosley, R. (2008). The FDA critical path initiative and its influence on new drug development. *Annual review of medicine*, *59*, 1–12. https://doi.org/10.1146/annurev.med.59.090506.155819
3. Schiff GD, Aggarwal HC, Kumar S, McNutt RA. Prescribing potassium despite hyperkalemia: medication errors uncovered by linking laboratory and pharmacy information systems. Am J Med. 2000;109:494-497.
4. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839-2844.

5. Bates DW, Cullen D, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995; 274:29-34.
6. Gandhi TK, Burstin HR, Cook EF, et al. Drug complications in outpatients. J Gen Intern Med. 2000;15:149-154.
7. President's Advisory Committee on Consumer Protection and Quality in Healthcare. Building the capacity to improve quality: investing in information systems. In: Quality First: Better Health Care for All Americans. Silver Spring, Md: Agency for Healthcare Research and Quality Publications Clearinghouse; 1998:chap 14.
8. Balas EA, Austin SM, Mitchell JA, Ewigman BG Bopp KD, Brown GD. The clinical value of computerized information services: areview of 98randomized clinical trials. Arch Fam Med 1996;5 271-278.
9. Berwick DM, Nolan TW. Overview: cooperating for improvement. Jt Comm J Qual Improv. 1995; 21:573-577.
10. David D. Pope, PharmD, CDE (2023). Pharmacies and Labs Must Work Together to Accelerate Test and Treat Opportunities, Enhance Patient Care Equity, Improve Health Outcomes. Pharmacies and Labs Must Work Together to Accelerate Test and Treat Opportunities, Enhance Patient Care Equity, Improve Health Outcomes (pharmacytimes.com).
11. Perry MJ. Chart of the Day… or Century? American Enterprise Institute. January 11, 2019. Accessed September 27, 2023. https://www.aei.org/carpe-diem/chart-of-the-day-or-century/#:~:text=During%20the%20most%20recent%2021,average%20hourly%20earnings%20(wages).
12. 31. Spicer J. Making patient care easier under multiple managed care plans. Fam Pract Manage. 1998;5(2):38-53.
13. Helfand M, Redfern CC, for the American College of Physicians. Clinical guideline, part 2 Screening for thyroid disease: an update. Ann Intern Med. 1998;129:144-158.
14. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35)prospective observational study. BMJ. 2000; 321:405-412.
15. Aronoff GR, Bennett WM. eds. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. 4th ed. Philadelphia, Pa: ACP-ASIM; 1999.
16. Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet. 1999;37:399-431.
17. Centers for Disease Control and Prevention. Druginduced liver injury: a national and global problem. Westfields Conference Center, Chantilly, Va, February 12-13, 2001. Available at: http://www.fda.gov/cder/livertox/default.htm. Accessed January 25, 2003.
18. Berenbrok LA, Tang S, Gabriel N, et al. Access to community pharmacies: A nationwide geographic information systems cross-sectional analysis. Sci and Pract. 2022;62(6):P1816-1822. doi:10.1016/j.japh.2022.07.003
19. Retail Health and Wellness Services Surge in Popularity, Driving Significant Gains in Pharmacy Customer Satisfaction, JD Power Finds. News release. JD Power. July 28, 2021. Accessed September 27, 2023. https://www.jdpower.com/business/press-releases/2021-us-pharmacy-study
20. Provider Status. Ohio Pharmacists Association. Accessed September 27, 2023. https://www.ohiopharmacists.org/aws/OPA/pt/sp/provider-status
21. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 2001;24:483-490.
22. Sundar S, Burma DP, Vaish SK. Digoxin toxicity and electrolytes: a correlative study. Acta Car- diol. 1983;38:115-123.
23. Young DS. Effects of Preanalytical Variables on Clinical Lab Tests. 2nd ed. Washington, DC: American Assocation for Clinical Chemistry Press; 1997.
24. Gronroos PE, Irjala KM, Huupponen RK, Schei- nin H, Forsstrom J, Forsstrom JJ. A medication database: a tool for detecting drug interactions in hospital. Eur J Clin Pharmacol. 1997;53:13- 17.
25. Forsstrom JJ, Gronroos P, Irjala K, Heiskanen J, Torniainen K. Linking patient medication data with laboratory information system. Int J Biomed Comput. 1996;42:111-116.
26. Kailajarvi M, Takala T, Gronroos P, et al. Reminders of drug effects on laboratory test results. Clin Chem. 2000;46:1395-1400.
27. Bill Malone (2012). The Emergence of Lab-Pharmacy Partnerships. The Emergence of Lab-Pharmacy Partnerships | myADLM.org.